222834-11-9

Upstream product

• 67-56-1 methanol 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 92199-64-9 2-(10H-phenoxazin-10-yl)-1-ethanol 
• 156335-15-8 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 222835-09-8 2-(10H-Phenoxazin-10-yl)ethyl methanesulfonate 
• 59012-91-8 2,2-dimethyl-propionic acid 4-hydroxymethyl-phenyl ester 
• 135-67-1 phenoxazine 
• 302344-84-9 ethyl 2-(10H-phenoxazin-10-yl)acetate 

Downstream Products

• 222834-30-2 (-)-2-ethoxy-3-(4-(2-phenoxazin-10-yl-ethoxy)-phenyl)-propionic acid 
• 222834-30-2 ragaglitazar 
• 222834-28-8 [(2S),N(1S)]-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxy-N-(2-hydroxy-1-phenylethyl)propanamide 

Relevant academic research and scientific papers

Asymmetric phase-transfer catalyzed glycolate alkylation, investigation of the scope, and application to the synthesis of (-)-ragaglitazar

Asymmetric glycolate alkylation using a protected acetophenone surrogate under solid-liquid phase-transfer conditions is a new approach to the synthesis of 2-hydroxy esters and acids. Diphenylmethyloxy-2,5-dimethoxyacetophenone 1 with a trifluorobenzyl ci

(-)3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

(-)DRF 2725 (6) is a phenoxazine analogue of phenyl propanoic acid. Compound 6 showed interesting dual activation of PPARα and PPARγ. In insulin resistant db/db mice, 6 showed better reduction of plasma glucose and triglyceride levels as compared to rosig

Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them

Novel beta -aryl- alpha -oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses.